Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (431-440 of 627) with videos related to

Pageof 63
Sort By:
American Heart Journal|August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialLuciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
Circulation. Cardiovascular Quality and Outcomes|September 1, 2020
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID TrialMarat Fudim, Charles W Hopley, Zhen Huang, et al.
American Heart Journal|November 30, 2019
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trialRachael Ward, Zhen Huang, Frank W Rockhold, et al.
ESC Heart Failure|February 17, 2021
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS ProgramJie Yu, Clare Arnott, Brendon L Neuen, et al.
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Journal of the American College of Cardiology|November 30, 1999
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trialK W Mahaffey, J A Puma, N A Barbagelata, et al.
Journal of Thrombosis and Thrombolysis|February 7, 2012
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trialSean van Diepen, Matthew T Roe, Renato D Lopes, et al.
American Heart Journal|October 11, 2011
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AFJonathan P Piccini, Elizabeth S Fraulo, Jack E Ansell, et al.
American Heart Journal|December 22, 2005
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla, Kenneth W Mahaffey, Shelly K Sapp, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 63

Showing results (431-440 of 627) with videos related to

Sort By:
Pageof 63
American Heart Journal|August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialLuciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
Circulation. Cardiovascular Quality and Outcomes|September 1, 2020
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID TrialMarat Fudim, Charles W Hopley, Zhen Huang, et al.
American Heart Journal|November 30, 2019
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trialRachael Ward, Zhen Huang, Frank W Rockhold, et al.
ESC Heart Failure|February 17, 2021
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS ProgramJie Yu, Clare Arnott, Brendon L Neuen, et al.
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Journal of the American College of Cardiology|November 30, 1999
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trialK W Mahaffey, J A Puma, N A Barbagelata, et al.
Journal of Thrombosis and Thrombolysis|February 7, 2012
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trialSean van Diepen, Matthew T Roe, Renato D Lopes, et al.
American Heart Journal|October 11, 2011
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AFJonathan P Piccini, Elizabeth S Fraulo, Jack E Ansell, et al.
American Heart Journal|December 22, 2005
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla, Kenneth W Mahaffey, Shelly K Sapp, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 63